Literature DB >> 35926460

Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development.

Daniel Williamson1, Edward C Schwalbe2, Debbie Hicks3, Kimberly A Aldinger4, Janet C Lindsey3, Stephen Crosier3, Stacey Richardson3, Jack Goddard3, Rebecca M Hill3, Jemma Castle3, Yura Grabovska5, James Hacking3, Barry Pizer6, Stephen B Wharton7, Thomas S Jacques8, Abhijit Joshi9, Simon Bailey3, Steven C Clifford10.   

Abstract

Medulloblastoma is currently subclassified into distinct DNA methylation subgroups/subtypes with particular clinico-molecular features. Using RNA sequencing (RNA-seq) in large, well-annotated cohorts of medulloblastoma, we show that transcriptionally group 3 and group 4 medulloblastomas exist as intermediates on a bipolar continuum between archetypal group 3 and group 4 entities. Continuum position is prognostic, reflecting a propensity for specific DNA copy-number changes, and specific switches in isoform/enhancer usage and RNA editing. Examining single-cell RNA-seq (scRNA-seq) profiles, we show that intratumoral transcriptional heterogeneity along the continuum is limited in a subtype-dependent manner. By integrating with a human scRNA-seq reference atlas, we show that this continuum is mirrored by an equivalent continuum of transcriptional cell types in early fetal cerebellar development. We identify distinct developmental niches for all four major subgroups and link each to a common developmental antecedent. Our findings show a transcriptional continuum arising from oncogenic disruption of highly specific fetal cerebellar cell types, linked to almost every aspect of group 3/group 4 molecular biology and clinico-pathology.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CP: cancer; development; genomics; medulloblastoma; pediatrics

Mesh:

Year:  2022        PMID: 35926460     DOI: 10.1016/j.celrep.2022.111162

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.995


  2 in total

1.  The origins of medulloblastoma tumours in humans.

Authors:  Timothy N Phoenix
Journal:  Nature       Date:  2022-09       Impact factor: 69.504

2.  Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation.

Authors:  Zhuoyao Chen; Rafael M Ioris; Stacey Richardson; Ava N Van Ess; Iolanda Vendrell; Benedikt M Kessler; Francesca M Buffa; Luca Busino; Steven C Clifford; Alex N Bullock; Vincenzo D'Angiolella
Journal:  Cell Death Differ       Date:  2022-04-04       Impact factor: 12.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.